NR3C2 and chronic myelogenous leukemia, BCR-ABL1 positive: Our in vitro data suggested that aldosterone-induced nitrotyrosine production was reduced by the treatment with Spiro (Fig. 5b), but it does not completely block the CML-induced MR activation (Fig. 6c).